The clinical course of a Mexican female with cystic fibrosis and the novel genotype S531P/S531P  by Laguna, Theresa A. et al.
Journal of Cystic Fibrosis 7 (2008) 454–456
www.elsevier.com/locate/jcfCase report
The clinical course of a Mexican female with cystic fibrosis
and the novel genotype S531P/S531P
Theresa A. Laguna a,b,⁎, Scott D. Sagel a,b, Marci K. Sontag c, Frank J. Accurso a,b
a Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital, 13123 E. 16th Ave, B-395; Aurora, CO; 80045, USA
b The Mike McMorris Cystic Fibrosis Research and Treatment Center, Aurora, Colorado, USA
c Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine, Denver, Colorado, USA. 4200 East Ninth Avenue,
B-119; Denver, CO; 80262, USA
Received 25 October 2007; received in revised form 8 January 2008; accepted 14 March 2008
Available online 6 May 2008Abstract
The case of a 16 year-old Mexican female with cystic fibrosis and the novel genotype S531P/S531P is presented. Her clinical course has
consisted of recurrent pancreatitis and rapidly progressive lung disease complicated by Mycobacterium kansasii and Penicillium infection. This
report illustrates the need for better characterization of CFTR mutations in a Hispanic population to aid in clinical care.
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Cystic fibrosis (CF) is an autosomal recessive disorder caused
by abnormalities in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) protein. Complications include pancreatic
insufficiency recurrent pancreatitis, malnutrition, fat-soluble
vitamin deficiencies, intestinal obstruction, male infertility and
progressive obstructive lung disease [1]. Over 1500 CFTR muta-
tions have been identified and classified as “mild” or “severe”
based on the severity of CFTR dysfunction [2]. While
approximately 70% of CF patients have at least one copy of the
CFTR mutation,ΔF508, only 39% of Mexican CF patients carry
this mutation [3]. Over 10% of patients in the US Cystic Fibrosis
Foundation patient registry have unknown CFTR mutations, and
this number increases in non-Caucasian populations [4]. In CF
patients with undefined genotyping, the clinical course may be
unpredictable and full CFTR gene sequencing/scanning may be
beneficial. We present a case of a Mexican girl with clinical
features of CF and the novel genotype S531P/S531P.⁎ Corresponding author. The Children's Hospital, Section of Pediatric
Pulmonology, 13123 E. 16th Ave, B-395, Aurora, CO 80045, USA. Tel.: +1
720 777 4532; fax: +1 720 777 7284.
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2.1. Presentation
A 16 year-old Mexican female presented with chronic
abdominal pain, multiple hospitalizations for pneumonia and
chronic cough. Height and weight were below the 5th percentile
and body mass index was 19.0 (25th percentile). She had no
reported history of steatorrhea. She had been living in the
United States for 10 years. Bronchiectasis was incidentally
noted at the lung bases on an abdominal computed tomography
(CT) scan performed for abdominal pain. She had no known
family history of CF.
2.2. Diagnostic studies
Sweat test by pilocarpine iontophoresis (at age 16) revealed
chloride of 70 mEq/L and sodium of 71 mEq/L. Repeat testing
(at age 18) revealed chloride of 38 mEq/L and sodium of
46 mEq/L. A nasal potential difference was attempted twice but
unattainable. CFTR gene analysis (Ambry Genetics®) revealed
the homozygous presence of a previously undescribed mutation,
S531P on exon 11, on a background of the poly T genotype 7T/
7T. Gross gene deletion(s)/duplication(s) testing was negative.d by Elsevier B.V. All rights reserved.
Fig. 2. HRCT of the chest during acute respiratory illness and fever. Reveals
persistent bronchiectasis and bilateral infiltrates with increasing consolidation of
the superior segment of the left lower lobe.
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480 mcg/g stool). Serum immunoreactive trypsinogen level was
50 ng/mL (10–57 ng/mL). Fat soluble vitamin levels were
normal. Pulmonary function testing revealed a forced expiratory
volume in one second (FEV1) of 1.71 L (80% predicted) and a
residual lung volume of 1.91 (273% predicted). Chest high-
resolution computed tomography (HRCT) revealed bilateral
bronchiectasis in the lower lobes, left worse than right, and air
trapping (Fig. 1). Sputum cultures grew Stenotrophomonas
maltophilia (1×104 cfu/mL), Staphylococcus aureus (1.3×
104 cfu/mL), and Penicillium species. Initial immunoglobulin E
level was 101 IU/mL (0–87 IU/mL). Purified-protein derivative
test was negative. Magnetic resonance cholangiopancreatogra-
phy revealed a pancreatic stone with obstruction and dilation of
the pancreatic duct.
2.3. Clinical course
Based on her clinical manifestations and initial sweat test, we
made a diagnosis of CF. She was diagnosed with chronic
pancreatitis and subsequent acute flares resulted in lipase levels
up to 1399 U/L (114–286 U/L). A pancreatic stent was placed
with no improvement and subsequently removed. Her pancrea-
titis has been treated with low dose pancrelipase enzyme
supplementation and a low-fat diet. She has required placement
of a gastro-jejunostomy tube for supplemental feedings. She
had been maintained on daily mucolytics and airway clearance
with a minimal decline in lung function.
Two years later, she was hospitalized for the acute onset of chest
pain, respiratory distress and high fever. Chest HRCT revealed
persistent bronchiectasis and bilateral infiltrates with consolidation
of the superior segment of the left lower lobe (Fig. 2). Symptoms
progressed without apparent etiology and thoracoscopic biopsy of
the left lung was performed. Specimen staining revealed acid fast
bacilli and Mycobacterium kansasii was confirmed on mycobac-
terial culture. Penicillium species were also isolated on fungal cul-
ture from the biopsy specimen. Four drug therapy forM. kansasii
was initiated which consisted of intravenous (IV) amikacin, oral
azithromycin, oral ethambutol, and oral rifampin. IV micafunginFig. 1. HRCT of the chest upon initial presentation. Reveals bilateral
bronchiectasis in the lower lobes and air trapping.was started for treatment of concurrent fungal pneumonia. Follow-
ing one week of therapy, her fever resolved and her respiratory
symptoms improved. She was discharged home on long-term
therapy for M. kansasii and Penicillium species. Since discharge,
she has remained fever free; however, her FEV1 has decreased to
1.33 L (53% predicted) with minimal improvement.
2.4. S531P mutation
To determine the frequency of this mutation in a Hispanic
population from the same community, we examined 42 Hispanic
patients (84 alleles) from our CF clinic who underwent full CFTR
gene sequencing. None of these carried the S531P mutation.
Thus, the incidence of this allele among Hispanic patients in our
clinic is 2.4% (95% CI, 0–8%).
3. Discussion
The identification of CFTR mutations in the Hispanic CF
population is important to allow for appropriate medical care and
genetic counseling of patients and families. This is challenging
given the low prevalence of CF in the Hispanic population of
approximately 1:6495–1:10,000 [5]. Numerous publications
have documented the broad spectrum of CFTR mutations present
in the Hispanic population and the number of unrecognized
mutations [6–8]. Since Hispanic CF patients have a more severe
clinical course than their Caucasian counterparts [9], there is need
to better characterize CFTR mutations and improve under-
standing of disease pathogenesis in this population.
We present a patient with the novel genotype S531P/S531P.
The mutation results from the substitution of T to C at nucleotide
position 1723 and changes the polar amino acid, serine, to a non-
polar amino acid, proline, within exon 11. Amino acid 531 is in
the cytoplasmic region between the sixth and seventh trans-
membrane regions, located in the ABC transporter 1 domain.
The amino acid substitution would likely affect the secondary
structure of CFTR and consequently affect tertiary structure (i.e.
folding). This mutation has resulted in CFTR dysfunction in our
456 T.A. Laguna et al. / Journal of Cystic Fibrosis 7 (2008) 454–456patient, although the sweat test showed significant variability
which has been previously described in pancreatic sufficient
infants with CF [5].
The patient has multiple phenotypical features consistent
with CF [10]. The clinical course has consisted of recurrent
pancreatitis and progressive obstructive lung disease compli-
cated by atypical mycobacterial infection with M. kansasii and
fungal infection with Penicillium species. M. kansasii infection
has been described in CF but is relatively rare and usually
carries a good prognosis [11,12]. Penicillium infection has been
implicated in hypersensitivity pneumonitis and immunosup-
pressive conditions, but the clinical significance of this organism
in CF is not well understood [13,14]. She has required long-term
antimicrobial therapy and supplemental nutrition, and her
prognosis remains unclear.
4. Conclusion
We found the homozygous presence of a previously
undescribed mutation, S531P, in this Mexican patient with severe
clinical manifestations of CF. Based on her clinical course, we
believe S531P is a disease-causing mutation and should be
examined in other Hispanics with CF and no previously detected
CFTR mutations.
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